ACXP — Acurx Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $32.62m
- $25.14m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 2.48 | 3.18 | 13 | 9.11 | 7.47 |
Net Total Receivables | — | — | — | — | 0.129 |
Prepaid Expenses | |||||
Total Current Assets | 2.53 | 3.22 | 13.3 | 9.38 | 7.71 |
Total Assets | 2.53 | 3.22 | 13.3 | 9.38 | 7.71 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.71 | 0.473 | 0.844 | 2.06 | 3.04 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 1.71 | 0.522 | 0.844 | 2.06 | 3.04 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.82 | 2.7 | 12.4 | 7.32 | 4.67 |
Total Liabilities & Shareholders' Equity | 2.53 | 3.22 | 13.3 | 9.38 | 7.71 |
Total Common Shares Outstanding |